King of Prussia, PA, United States of America

Michelle Spatara

USPTO Granted Patents = 9 

Average Co-Inventor Count = 4.0

ph-index = 3

Forward Citations = 19(Granted Patents)


Company Filing History:


Years Active: 2020-2025

Loading Chart...
9 patents (USPTO):Explore Patents

Title: The Innovations of Inventor Michelle Spatara

Introduction

Michelle Spatara, an accomplished inventor based in King of Prussia, Pennsylvania, has made significant contributions to the field of biopharmaceuticals. With a portfolio of eight patents, she has dedicated her career to advancing medical technology and improving treatment options for various diseases.

Latest Patents

Among her most recent innovations are groundbreaking biopharmaceutical compositions aimed at treating interleukin 5 (IL-5) mediated diseases. These compositions and related methods demonstrate her commitment to addressing complex health challenges through innovative solutions.

Career Highlights

Michelle is currently associated with GlaxoSmithKline Intellectual Property (No. 2) Limited, where her expertise is instrumental in the development of novel medical therapies. Throughout her career, she has consistently focused on translating scientific research into practical applications that benefit patients worldwide.

Collaborations

In her journey, Michelle has collaborated with notable colleagues such as Myrna A. Monck and Narendra B. Bam. These partnerships have facilitated the exchange of ideas and propelled the development of innovative treatments, showcasing the power of teamwork in driving scientific progress.

Conclusion

With her impressive track record and unwavering commitment to innovation, Michelle Spatara stands out as a key figure in the realm of biopharmaceutical research. Her contributions promise to enhance therapeutic options and improve the quality of life for many individuals affected by IL-5 mediated diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…